Inside Rentschler Biopharma’s Stevenage Site for Advanced Therapies

Robert Panting, General Manager of our ATMP business, recently sat down with Christopher Day, Reporter at the Comet, to discuss the innovative work at our facility in Stevenage, UK. 

Rentschler Biopharma’s UK facility was launched in 2021 to provide high-quality viral vectors for advanced therapy medicinal products (ATMPs). The site is located in the largest cell and gene therapy (CGT) cluster in Europe and is dedicated to advancing CGT products from development to cGMP manufacturing for our clients and their patients. 

Cell and gene therapies (CGTs) are  relatively new modalities for the biopharmaceutical industry that, where successful, could be used to address the unique needs of patients with often rare or previously untreated diseases.  

“This is a really exciting area of science to be in; advanced therapies coming out onto the market and being developed that in 20 years’ time will make it a very different place for patients”. Robert Panting, General Manager, ATMP

Read the full article to get inspired by the innovative and impactful work being done at our Stevenage site, contributing to the advancement of CGT products and the local biotech ecosystem.

Read the full article here

Rentschler Biopharma news Latika Bhonsle-Deeng

Corporate Spokesperson

Rentschler Biopharma SE

Dr. Latika Bhonsle-Deeng
Head of Communications

Get in touch